TY - JOUR
T1 - Functional Immune Cell-Derived Exosomes Engineered for the Trilogy of Radiotherapy Sensitization
AU - Ma, Xiaotu
AU - Yao, Meinan
AU - Gao, Yu
AU - Yue, Yale
AU - Li, Yao
AU - Zhang, Tianjiao
AU - Nie, Guangjun
AU - Zhao, Xiao
AU - Liang, Xiaolong
N1 - Funding Information:
This work was supported by the National Natural Science Foundation of China (81771846), the Beijing Talents Foundation (2018000021223ZK48), and grants from Peking University Third Hospital (BYSYZD2019018, jyzc2018-02, and BYSY2015023).
Publisher Copyright:
© 2022 The Authors. Advanced Science published by Wiley-VCH GmbH.
PY - 2022/8/15
Y1 - 2022/8/15
N2 - The limited efficacy of radiotherapy leads to radio-resistance and high rates of tumor recurrence and metastasis, which is caused by tumor hypoxia, rapid DNA damage repair, and especially the suppressive immune microenvironment of tumor. Lots of immune cell-derived exosomes can regulate antitumor immunity, but their application in enhancing radiotherapy is rarely studied. Herein, as a model of concept, M1 macrophage-derived exosomes (M1Exos) is engineered as effective radiotherapy sensitizers, realizing the trilogy of radiotherapy sensitization: 1) M1Exos is engineered to express catalases on the inside of membrane, which can effectively relieve tumor hypoxia, and enhance DNA damage. 2) The DNA damage repair inhibitor is loaded in M1Exos to effectively inhibit DNA damage repair. 3) M1Exos can polarize M2 macrophages into M1 phenotypes, and the anti-PD-L1 nanobody engineered on the outside of M1Exos can relieve the immunosuppression of T cells, both ultimately leading to the remodeling of the tumor suppressive microenvironment. The trilogy of radiotherapy sensitization achieves excellent antitumor efficacy, exhibiting the good utility of engineering immune cell-derived exosomes as radiotherapy sensitizers, inspiring the future efforts to explore different kinds of immune cell-derived exosomes for enhanced radiotherapy.
AB - The limited efficacy of radiotherapy leads to radio-resistance and high rates of tumor recurrence and metastasis, which is caused by tumor hypoxia, rapid DNA damage repair, and especially the suppressive immune microenvironment of tumor. Lots of immune cell-derived exosomes can regulate antitumor immunity, but their application in enhancing radiotherapy is rarely studied. Herein, as a model of concept, M1 macrophage-derived exosomes (M1Exos) is engineered as effective radiotherapy sensitizers, realizing the trilogy of radiotherapy sensitization: 1) M1Exos is engineered to express catalases on the inside of membrane, which can effectively relieve tumor hypoxia, and enhance DNA damage. 2) The DNA damage repair inhibitor is loaded in M1Exos to effectively inhibit DNA damage repair. 3) M1Exos can polarize M2 macrophages into M1 phenotypes, and the anti-PD-L1 nanobody engineered on the outside of M1Exos can relieve the immunosuppression of T cells, both ultimately leading to the remodeling of the tumor suppressive microenvironment. The trilogy of radiotherapy sensitization achieves excellent antitumor efficacy, exhibiting the good utility of engineering immune cell-derived exosomes as radiotherapy sensitizers, inspiring the future efforts to explore different kinds of immune cell-derived exosomes for enhanced radiotherapy.
KW - engineered exosome
KW - immune microenvironment
KW - macrophage polarization
KW - radiotherapy sensitization
KW - tumor hypoxia
UR - http://www.scopus.com/inward/record.url?scp=85132027019&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85132027019&partnerID=8YFLogxK
U2 - 10.1002/advs.202106031
DO - 10.1002/advs.202106031
M3 - Article
C2 - 35715382
AN - SCOPUS:85132027019
VL - 9
JO - Advanced Science
JF - Advanced Science
SN - 2198-3844
IS - 23
M1 - 2106031
ER -